{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:40:39Z","timestamp":1788313239996,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Glucagon-like peptide 1 (GLP-1) receptor agonists, medications commonly employed in the treatment of type 2 diabetes mellitus, have illustrated several additional benefits, including weight loss and potentially reduce addictive cravings. Several studies have indicated that GLP-1 receptor agonists may be effective in treating Alcohol Use Disorder (AUD), for which current pharmacologic therapies are often inadequate. Proposed mechanisms include modulation of dopaminergic transmission and reduced gastric emptying, both of which reduce alcohol craving and tolerance. This case report discusses dulaglutide\u2019s ability to reduce alcohol consumption. During a visit to an outpatient behavioral health clinic, a 44-year-old male was evaluated for weight loss. His medical history revealed a BMI of 41.8, hypertension, major depressive disorder, and pre-diabetes. The individual also reported the consumption of approximately ninety beers per month and was in the pre-contemplation phase of change. As part of the treatment plan, the patient was prescribed dulaglutide to manage pre-diabetes and facilitate weight loss. During subsequent appointments, the individual not only experienced weight loss but also noted a substantial reduction in alcohol cravings and consumption. However, following a lapse in insurance coverage the following year, the individual had to discontinue his dulaglutide, resulting in a return to previous drinking patterns. Future research should focus on confirming existing animal study results in humans, with the hope that GLP-1 receptor agonists can become a mainstay treatment for AUD.<\/jats:p>","DOI":"10.3389\/fpsyt.2025.1420316","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T01:38:17Z","timestamp":1746063497000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of dulaglutide in the treatment of alcohol use disorder: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Olivia","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aakanksha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ang-Rabanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Mogallapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"B1","volume-title":"Alcohol\u2019s Effects on Health","year":"2024"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders","volume":"373","author":"Rehm","year":"2009","journal-title":"Lancet"},{"key":"B3","unstructured":"Alcohol use disorders identification test (audit)"},{"key":"B4","volume-title":"Medications for alcohol use disorder","author":"Winslow","year":"2016"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2020.614884","article-title":"Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on Palatable Food, drugs of abuse, and alcohol","volume":"14","author":"Eren-Yazicioglu","year":"2021","journal-title":"Front Behav Neurosci"},{"key":"B6","article-title":"Neuroplasticity in human alcoholism","volume":"37","author":"Fein","year":"2015","journal-title":"Alcohol Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.68","article-title":"The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: Evidence from Human Genetic Association Studies and a mouse model of alcohol dependence","volume":"5","author":"Suchankova","year":"2015","journal-title":"Trans Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2011.02.028","article-title":"Insulin signaling and addiction","volume":"61","author":"Daws","year":"2011","journal-title":"Neuropharmacology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19761","article-title":"Pharmacotherapy for alcohol use disorder: A systematic review and meta-analysis","volume":"330","author":"McPheeters","year":"2023","journal-title":"JAMA"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069010","article-title":"The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.6326-11.2012","article-title":"The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: A new role for mesolimbic GLP-1 receptors","volume":"32","author":"Dickson","year":"2012","journal-title":"J Neurosci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12295","article-title":"The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents","volume":"21","author":"Vall\u00f6f","year":"2015","journal-title":"Addict Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.02.020","article-title":"Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents","volume":"149","author":"Vall\u00f6f","year":"2019","journal-title":"Neuropharmacology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pbb.2017.07.014","article-title":"The glucagon-like peptide 1 receptor agonist exendin-4 decreases relapse-like drinking in socially housed mice","volume":"160","author":"Thomsen","year":"2017","journal-title":"Pharmacol Biochem Behav"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2019.146562","article-title":"Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1","volume":"1727","author":"Jerlhag","year":"2020","journal-title":"Brain Res"},{"key":"B18","article-title":"Neuroplasticity and predictors of alcohol recovery","volume":"37","author":"Seo","year":"2015","journal-title":"Alcohol Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104772","article-title":"Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent","volume":"138","author":"Jensen","year":"2020","journal-title":"Neurochemistry Int"},{"key":"B20","doi-asserted-by":"publisher","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"243599","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"13","author":"Lahteenvuo","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.112424","article-title":"Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials","volume":"264","author":"Martinelli","year":"2024","journal-title":"Drug Alcohol Dependence"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: A case series","volume":"85","author":"Richards","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCl Insight"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/0033294120971750","article-title":"Binge eating and addictive-like behaviours in males and females","volume":"125","author":"Levallius","year":"2020","journal-title":"psychol Rep"},{"key":"B26","article-title":"Site and quantitative importance of alcohol first-pass metabolism","volume":"24","author":"Baraona","year":"2000","journal-title":"Alcohol Clin Exp Res"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1420316\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T01:38:20Z","timestamp":1746063500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1420316\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":26,"alternative-id":["10.3389\/fpsyt.2025.1420316"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1420316","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"article-number":"1420316"}}